No connection

Search Results

HIND vs ZJYL

HIND
Vyome Holdings, Inc.
BEARISH
Price
$2.19
Market Cap
$15.4M
Sector
Healthcare
AI Confidence
95%
ZJYL
Jin Medical International Ltd.
BEARISH
Price
$2.15
Market Cap
$16.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HIND
--
ZJYL
10.78
Forward P/E
HIND
--
ZJYL
--
P/B Ratio
HIND
5.3
ZJYL
0.57
P/S Ratio
HIND
48.08
ZJYL
0.82
EV/EBITDA
HIND
-4.29
ZJYL
7.14

Profitability

Gross Margin
HIND
68.43%
ZJYL
30.18%
Operating Margin
HIND
-3707.35%
ZJYL
9.83%
Profit Margin
HIND
0.0%
ZJYL
5.76%
ROE
HIND
--
ZJYL
4.75%
ROA
HIND
-43.58%
ZJYL
0.77%

Growth

Revenue Growth
HIND
-40.5%
ZJYL
-16.5%
Earnings Growth
HIND
--
ZJYL
-32.0%

Financial Health

Debt/Equity
HIND
0.01
ZJYL
0.64
Current Ratio
HIND
1.99
ZJYL
1.85
Quick Ratio
HIND
1.86
ZJYL
1.53

Dividends

Dividend Yield
HIND
--
ZJYL
--
Payout Ratio
HIND
0.0%
ZJYL
0.0%

AI Verdict

HIND BEARISH

Vyome Holdings (HIND) presents a high-risk profile characterized by a catastrophic collapse in share price (-96.1% over 1 year) and severe operational inefficiency. While the Piotroski F-Score of 5/9 suggests a 'stable' baseline in terms of basic financial structure, this is overshadowed by an operating margin of -3707.35% and a massive earnings miss of -2736.4%. The company is trading at an unsustainable Price/Sales ratio of 48.08 despite revenue declining by 40.5% YoY, indicating a complete disconnect between valuation and fundamental performance.

Strengths
Very low leverage with a Debt/Equity ratio of 0.01
Strong Gross Margin of 68.43%, typical for biotechnology
Adequate short-term liquidity with a Current Ratio of 1.99
Risks
Extreme operational losses (Operating Margin -3707.35%)
Significant revenue contraction (-40.50% YoY)
Severe price devaluation, trading near 52-week lows after a 96% drop
ZJYL BEARISH

ZJYL presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 6/9 and a price significantly below its Graham Number ($4.13), yet plagued by severe fundamental decay. While the company maintains a healthy balance sheet with a current ratio of 1.85 and low debt/equity (0.64), it is suffering from catastrophic growth contraction, with revenue down 16.5% and earnings down 32% YoY. The massive 87.7% decline in share price over the last year reflects a market that has completely lost confidence in the company's growth trajectory. Despite trading at a deep discount to book value (P/B 0.57), the lack of positive catalysts and bearish technical trend outweigh the valuation appeal.

Strengths
Trading significantly below book value (P/B 0.57)
Stable financial health indicated by Piotroski F-Score of 6/9
Strong liquidity position with a Current Ratio of 1.85
Risks
Severe revenue contraction (-16.5% YoY)
Sharp decline in earnings growth (-32% YoY)
Catastrophic 1-year price performance (-87.7%)

Compare Another Pair

HIND vs ZJYL: Head-to-Head Comparison

This page compares Vyome Holdings, Inc. (HIND) and Jin Medical International Ltd. (ZJYL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile